Intracellular expression of cellular eIF-5A mutants inhibits HIV-1 replication in human T cells: a feasibility study.

Previously, we described two mutants of the cellular Rev co-factor, eukaryotic initiation factor 5A (eIF-5A M13 and M14), which suppress human immunodeficiency virus type 1 (HIV-1) SF2 replication in clonal T cell lines. This study introduced the notion that it is possible to develop gene therapies against infectious agents on the basis of mutant host factors required for viral replication. In this report, we provide further evidence to support this new paradigm and describe murine leukemia virus (MLV)-based retroviral vectors expressing three different eIF-5A mutants from the viral long terminal repeat (LTR). HIV-1 replication (SF2, HXB-3) was reduced up to 2 orders of magnitude in transduced, polyclonal T cell populations. All eIF-5A mutants also showed antiviral activity (approximately seven-fold reduction) in a chronic HIV-1 infection model. Expression of eIF-5A mutant M13 delta in peripheral blood lymphocytes (PBLs) showed no difference in proliferation and metabolic activity as determined in a 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT)-assay, suggesting that expression of this type of mutant protein is not associated with cellular toxicity. In summary, these data suggest that gene therapy for HIV-1 infection can be developed on the basis of mutants of the Rev co-factor eIF-5A.
AuthorsU Junker, D Bevec, C Barske, C Kalfoglou, S Escaich, M Dobrovnik, J Hauber, E Böhnlein
JournalHuman gene therapy (Hum Gene Ther) Vol. 7 Issue 15 Pg. 1861-9 (Oct 1 1996) ISSN: 1043-0342 [Print] UNITED STATES
PMID8894678 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Peptide Initiation Factors
  • RNA-Binding Proteins
  • eukaryotic translation initiation factor 5A
  • Blotting, Northern
  • Blotting, Southern
  • Feasibility Studies
  • Genetic Therapy (methods)
  • Genetic Vectors
  • HIV-1 (physiology)
  • Humans
  • Mutagenesis, Site-Directed
  • Peptide Initiation Factors (genetics)
  • RNA-Binding Proteins
  • Retroviridae
  • Virus Replication (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: